← Back to Search

Dietary Supplement

Beta-glucan for Lung Cancer

N/A
Recruiting
Led By Goetz H Kloecker, MD
Research Sponsored by University of Louisville
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
Must not have
Currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
Presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-treatment
Awards & highlights

Summary

This trial will study how well beta-glucan works in boosting the immune system of people with non-small cell lung cancer.

Who is the study for?
This trial is for adults who can swallow pills, have a certain level of physical fitness (ECOG 0-3), and enough white blood cells (ANC at least 1500/microl). They must be able to consent, have operable non-small cell lung cancer, and not received treatment in the last 6 months. It's not for those allergic to beta-glucan or on steroids/immunosuppressants, or with uncontrolled illnesses or psychiatric conditions.
What is being tested?
The study is testing how beta-glucan affects the immune system in patients with non-small cell lung cancer. Participants will take beta-glucan orally to see if it helps their body fight cancer.
What are the potential side effects?
Potential side effects are not specified but may include reactions related to immune system changes due to beta-glucan. Patients with previous hypersensitivity reactions to beta-glucan are excluded from the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with non-small cell lung cancer.
Select...
I can care for myself but may not be able to do heavy physical work.
Select...
My lung cancer can be removed with surgery, as confirmed by a thoracic surgeon.
Select...
I am fit for surgery.
Select...
I can swallow pills.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on continuous corticosteroids or other immunosuppressive drugs.
Select...
I do not have any severe illnesses that could interfere with the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-treatment and post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-treatment and post-treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
blood specimens will be obtained to examine the ability of beta-glucan to prime neutrophils complement receptor 3 (CR3) and test the cytotoxicity of the primed neutrophils.
resected lung tissue will be tested to determine macrophage phenotype

Trial Design

2Treatment groups
Experimental Treatment
Group I: AIM 3: subjects with resectable NSCLCExperimental Treatment1 Intervention
1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
Group II: AIM 2: subjects with suspected or definitive NSCLC diagnosisExperimental Treatment1 Intervention
1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
beta-glucan
2005
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

University of LouisvilleLead Sponsor
342 Previous Clinical Trials
77,033 Total Patients Enrolled
James Graham Brown Cancer CenterOTHER
43 Previous Clinical Trials
8,918 Total Patients Enrolled
Goetz H Kloecker, MDPrincipal InvestigatorJames Graham Brown Cancer Center
5 Previous Clinical Trials
103 Total Patients Enrolled

Media Library

Beta-glucan (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT00682032 — N/A
Non-Small Cell Lung Cancer Research Study Groups: AIM 2: subjects with suspected or definitive NSCLC diagnosis, AIM 3: subjects with resectable NSCLC
Non-Small Cell Lung Cancer Clinical Trial 2023: Beta-glucan Highlights & Side Effects. Trial Name: NCT00682032 — N/A
Beta-glucan (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00682032 — N/A
~18 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top